| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website https://www.jocmr.org |
Short Communication
Volume 16, Number 2-3, March 2024, pages 124-127
Alpha-1 Antitrypsin Phenotyping: An Unmet Educational Need of Healthcare Providers
Table
| Demographics | Phenotype performed (n = 13) | No phenotype performed (n = 17) | P value |
|---|---|---|---|
| Data are expressed as means ± standard deviation (SD) where appropriate. FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lungs for carbon monoxide. | |||
| Age (years) | 61 (19) | 51 (17) | 0.145 |
| Male, n (%) | 12 (92) | 15 (88) | 0.719 |
| Body mass index (kg/m2) | 28.6 (6.4) | 29.2 (4.7) | 0.783 |
| African Americans, n (%) | 7 (54) | 7 (41) | 0.478 |
| Hispanics, n (%) | 1 (8) | 3 (18) | 0.43 |
| Whites, n (%) | 5 (38) | 7 (41) | 0.865 |
| Alpha-1 antitrypsin (mg/dL) | 77.6 (5.7) | 91.6 (9.2) | 0.009 |
| Hypertension, n (%) | 5 | 2 | 0.189 |
| Diabetes mellitus, n (%) | 3 | 2 | 0.678 |
| Heart disease, n (%) | 5 | 2 | 0.189 |
| Current or former smoker, n (%) | 9 (69) | 8 (47) | 0.23 |
| Chronic lung disease, n (%) | 9 (69) | 5 (29) | 0.063 |
| Chronic liver disease, n (%) | 3 (23) | 11 (65) | 0.033 |
| Chronic lung and liver disease, n (%) | 1 (8) | 1 (6) | - |
| Pulmonary function tests | |||
| FEV1 (L) | 2.7 (1.5) | 2.2 (1.1) | 0.474 |
| FEV1 % predicted | 70 (18) | 61 (22) | 0.38 |
| DLCO (mL/min/mm Hg) | 21 (10.5) | 14.7 (8.5) | 0.308 |
| DLCO % predicted | 68 (27) | 54 (30.3) | 0.375 |